Yangtze River Pharmaceutical Group

Located in Nanjing, the Yangtze River Pharmaceutical Group pharmaceutical laboratory supports advanced research and development activities for one of China’s foremost pharmaceutical corporations.

Completed in 2023, the Nanjing pharmaceutical laboratory is part of the broader research infrastructure for Yangtze River Pharmaceutical Group, a large-scale Chinese multinational pharmaceutical corporation founded in 1971 and headquartered in Taizhou. The group has established multiple differentiated R&D bases across China and maintains a sustained focus on research-driven innovation in drug development and healthcare solutions.

Yangtze River Pharmaceutical Group’s product portfolio spans active pharmaceutical ingredients, finished medicines, and biologics, with an international presence in over 40 countries and regions. The company’s commitment to innovation is supported by extensive research teams and platforms aiming to address unmet medical needs while enhancing global health outcomes.

The Nanjing laboratory project not only optimized the spatial layout of scientific research areas but also elevated environmental quality and operational functionality to pharmaceutical-grade standards, aligning with the group’s pursuit of excellence in innovation and quality. Customized solutions were implemented to meet the complex demands of laboratory settings—including high-precision instrument zones and integrated office spaces—providing an efficient and adaptive environment for scientific operations.